Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Chemotherapy and Radiotherapy for Inoperable Pancreatic Cancer
NCT06050317Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in pancreatic cancer (PC), sponsored by Shandong Cancer Hospital. Started Aug 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06050317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050317.